Brown Advisory Securities LLC cut its stake in Bristol-Myers Squibb Company (NYSE:BMY) by 17.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 19,082 shares of the biopharmaceutical company’s stock after selling 4,141 shares during the period. Brown Advisory Securities LLC’s holdings in Bristol-Myers Squibb were worth $1,039,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Dodge & Cox acquired a new position in Bristol-Myers Squibb during the fourth quarter valued at $1,316,815,000. Quadrature Capital Ltd boosted its position in Bristol-Myers Squibb by 43.6% in the fourth quarter. Quadrature Capital Ltd now owns 170,689 shares of the biopharmaceutical company’s stock valued at $9,977,000 after buying an additional 51,825 shares in the last quarter. Pekin Singer Strauss Asset Management IL boosted its position in Bristol-Myers Squibb by 3.5% in the fourth quarter. Pekin Singer Strauss Asset Management IL now owns 35,331 shares of the biopharmaceutical company’s stock valued at $2,065,000 after buying an additional 1,200 shares in the last quarter. Wealthfront Inc. boosted its position in Bristol-Myers Squibb by 155.6% in the fourth quarter. Wealthfront Inc. now owns 35,512 shares of the biopharmaceutical company’s stock valued at $2,075,000 after buying an additional 21,617 shares in the last quarter. Finally, RMB Capital Management LLC boosted its position in Bristol-Myers Squibb by 7.3% in the fourth quarter. RMB Capital Management LLC now owns 187,648 shares of the biopharmaceutical company’s stock valued at $10,966,000 after buying an additional 12,800 shares in the last quarter. Hedge funds and other institutional investors own 69.79% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE BMY) traded up 0.51% during mid-day trading on Friday, reaching $56.88. The company’s stock had a trading volume of 906,429 shares. The firm has a market cap of $93.28 billion, a P/E ratio of 20.77 and a beta of 1.17. The firm’s 50-day moving average price is $55.82 and its 200 day moving average price is $54.60. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $61.30.
Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company’s revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the business posted $0.69 EPS. On average, analysts expect that Bristol-Myers Squibb Company will post $2.97 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Wednesday, July 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.76%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.
ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2017/08/11/bristol-myers-squibb-company-bmy-stake-decreased-by-brown-advisory-securities-llc.html.
Several research analysts have recently weighed in on BMY shares. BMO Capital Markets restated a “market perform” rating and issued a $45.00 price target on shares of Bristol-Myers Squibb in a research note on Sunday, April 23rd. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $59.88 price target for the company. in a research note on Monday, April 24th. Robert W. Baird initiated coverage on Bristol-Myers Squibb in a research note on Tuesday, April 25th. They issued an “outperform” rating for the company. Jefferies Group LLC reiterated a “buy” rating and set a $64.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday, June 5th. Finally, BidaskClub upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $62.69.
In related news, Director Theodore R. Samuels II acquired 6,000 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, August 2nd. The stock was acquired at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the purchase, the director now owns 18,000 shares of the company’s stock, valued at approximately $1,006,920. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.23% of the company’s stock.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
What are top analysts saying about Bristol-Myers Squibb Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb Company and related companies.